Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Miravo Healthcare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$2.0 million","newsHeadline":"Miravo Healthcare Ireland Enters into Suvexx\u00ae License and Supply Agreement with Orion Corporation for Select EU Markets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Receives Final Approvl for Generic Version of GlaxoSmithKline\u2019s IMITREX\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$22.0 million","newsHeadline":"Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upsher-Smith Laboratories, LLC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$22.0 million","newsHeadline":"Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Nuvo Pharmaceuticals","sponsor":"Orion Corporation","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"Searchlight Pharma Announces Suvexx\u00ae Launch in Europe, Along with Deal Expansion to all E.U. Markets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Sumatriptan Succinate

    Menu

    Sumatriptan Succinate

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Nuvo Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Searchlight Pharma Announces Suvexx® Launch in Europe, Along with Deal Expansion to all E.U. Markets

              Details:

              The agreement aims for the exclusive right to package, distribute, market and sell Suvexx, a patent protected, fixed dose combination of naproxen sodium and sumatriptan approved for the acute treatment of migraine attacks in adults, in all remaining E.U. countries.

              Lead Product(s): Naproxen Sodium,Sumatriptan

              Therapeutic Area: Neurology Product Name: Suvexx

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Orion Corporation

              Deal Size: $0.6 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement August 15, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Upsher-Smith Laboratories

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products

              Details:

              Through the acquisition, Tonix gets two FDA approved products including, Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray), indicated for the treatment of acute migraine in adults.

              Lead Product(s): Sumatriptan

              Therapeutic Area: Neurology Product Name: Zembrace SymTouch

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Tonix Pharmaceuticals Holding Corp

              Deal Size: $25.0 million Upfront Cash: $22.0 million

              Deal Type: Acquisition July 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Upsher-Smith Laboratories

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upsher-Smith Laboratories, LLC

              Details:

              The acquisition of two currently-marketed products Zembrace SymTouch (sumatriptan succinate injection) and Tosymra (sumatriptan nasal spray), complement Tonix’s current intranasal clinical development program of TNX-1900 for migraine prevention.

              Lead Product(s): Sumatriptan

              Therapeutic Area: Neurology Product Name: Zembrace SymTouch

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Tonix Pharmaceuticals Holding Corp

              Deal Size: $25.0 million Upfront Cash: $22.0 million

              Deal Type: Acquisition June 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cipla

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cipla Receives Final Approvl for Generic Version of GlaxoSmithKline’s IMITREX®

              Details:

              Cipla’s Sumatriptan Nasal Spray USP, 20 mg is an AB-rated generic therapeutic equivalent version of GlaxoSmithKline’s Imitrex® Nasal Spray.

              Lead Product(s): Sumatriptan

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 02, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Miravo Healthcare

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Miravo Healthcare Ireland Enters into Suvexx® License and Supply Agreement with Orion Corporation for Select EU Markets

              Details:

              Miravo Healthcare, has entered into an exclusive license and supply agreement with Orion Corporation for the exclusive right to package, distribute, market and sell Suvexx in Finland, Sweden, Denmark, Norway, Poland, Hungary, Latvia, Lithuania and Estonia.

              Lead Product(s): Naproxen Sodium,Sumatriptan

              Therapeutic Area: Neurology Product Name: Suvexx

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Orion Corporation

              Deal Size: Undisclosed Upfront Cash: $2.0 million

              Deal Type: Partnership December 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY